EE
EEP.MC Euroespes S.A.
- Market cap
- EUR 3.95M
- P/E
- -
- P/B
- 0.88x
- ROE
- 0.0%
- Dividend yield
- -
- Fundamental score
- 1.1/5
Ratios use the latest price and the fiscal year ending Dec 2025.
Is EEP.MC undervalued?
Graham numberThe Graham number of Euroespes S.A. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Euroespes S.A. fundamental analysis
6 of 22 checks passedROE 0/2
Low return on equity (0.0%), below 10%.
ROA 1/1
Return on assets (0.0%) is above the industry median (-1.9%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (100.3%) is above the industry median (41.0%).
Revenue Growth 0/2
Revenue shrank 4.4% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 0/1
Current assets do not cover long-term liabilities.
Debt to Equity 1/2
Moderate debt to equity (48.1%), up to 100%.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 0/1
EBIT is negative, against interest expense, below 5x.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (0.9x) is below the industry median (2.0x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Euroespes S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Euroespes S.A.
Euroespes, S.A., a medical center, provides medical services for the research, diagnosis, and treatment of central nervous system disorders and other diseases in Spain and internationally. It offers personalized and genomic medicine services for predictive, diagnostic, and therapeutic purposes. The company also provides medical services, such as neuro-ophthalmology, neuro-otorhinolaryngology, neuropsychology, digital diagnostics, radiodiagnosis, clinical analysis laboratory,…
Full company profileEuroespes S.A. financial statements
Euroespes S.A. annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 2.53M | 2.60M | 2.55M | 2.37M | 2.52M | 3.29M | 3.30M | 2.95M | 2.91M | 2.88M |
| Gross Profit | 2.94M | 2.78M | 2.17M | 2.11M | 2.38M | 3.19M | 1.70M | 2.71M | 2.57M | 2.59M |
| Operating Income | 390K | 407K | -249K | -827K | -335K | -247K | -1.39M | -1.41M | -257K | 41.6K |
| EBITDA | - | 671K | 111K | -242K | 230K | 665K | -193K | - | - | - |
| Net Income | 343K | 105K | -254K | -1.26M | -411K | -183K | -1.14M | -2.13M | -323K | 923.08 |
| EPS | - | 0.02 | -0.02 | -0.12 | -0.04 | -0.02 | -0.10 | -0.18 | -0.03 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | 8.90M | 9.35M | 12.8M | 11.4M | 11.7M | 12.3M | 11.4M | 7.93M | 6.94M | 6.42M |
| Total Liabilities | 4.63M | 4.78M | 3.96M | 3.92M | 4.26M | 4.82M | 5.22M | 5.04M | 4.37M | 3.77M |
| Shareholders' Equity | 3.81M | 4.10M | 8.41M | 7.14M | 7.44M | 7.43M | 6.20M | 2.89M | 2.57M | 2.65M |
| Cash & Short-term Investments | 71.1K | 17.1K | 3.43M | 2.34M | 2.24M | 1.99M | 974K | 423K | 217K | 443K |
| Cash Flow | ||||||||||
| Operating Cash Flow | 451K | 912K | 45.5K | -510K | -288K | 16.6K | -648K | 556K | 70.5K | 622K |
| Capital Expenditure | 7.07K | 232K | 109K | 231K | 60.3K | 95.0K | 717K | 523K | 201K | 246K |
| Free Cash Flow | - | -141K | -461K | -805K | -430K | -184K | -1.36M | 32.8K | -130K | 377K |
| Ratios | ||||||||||
| ROE | 9.0% | 2.6% | -3.0% | -17.6% | -5.5% | -2.5% | -18.3% | -73.8% | -12.6% | 0.0% |
| ROA | 3.9% | 1.1% | -2.0% | -11.1% | -3.5% | -1.5% | -10.0% | -26.9% | -4.7% | 0.0% |
| Net Profit Margin | 13.6% | 4.1% | -10.0% | -53.0% | -16.3% | -5.6% | -34.5% | -72.3% | -11.1% | 0.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Euroespes S.A. dividends
Euroespes S.A. has not paid dividends in the last 10 fiscal years.
Who owns Euroespes S.A.
- Insiders 67.49%
- Institutions 3.17%
- Public & others 29.34%
- Shares outstanding 11.6M
- Free float 8.65M
Euroespes S.A. company profile
- Company name
- Euroespes S.A.
- Ticker
- EEP.MC
- ISIN
- ES0133421000
- Exchange
- Madrid Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 39
- Fiscal year end
- December
- Address
- Santa Marta de BabIo s/n, Corunna, Spain, 15165
- Phone
- 34 981 780 505
- Website
- euroespes.com
About Euroespes S.A.
Euroespes, S.A., a medical center, provides medical services for the research, diagnosis, and treatment of central nervous system disorders and other diseases in Spain and internationally. It offers personalized and genomic medicine services for predictive, diagnostic, and therapeutic purposes. The company also provides medical services, such as neuro-ophthalmology, neuro-otorhinolaryngology, neuropsychology, digital diagnostics, radiodiagnosis, clinical analysis laboratory, nursing, and cardiology. In addition, it researches and develops in the fields of biochemistry, health biotechnology, epigenetics, pharmacogenomics, and nutraceuticals. The company was founded in 1991 and is based in Corunna, Spain.
Euroespes S.A. management
2- Mr. Ramon Cacabelos GarciaPresident of the Board & CEO
- Mr. Francisco Javier Casal LlorenteSecretary of the Board